Idecabtagene Vicleucel (Ide-Cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3 Christoph Scheid , Paula Rodriguez-Otero , Sikander Ailawadhi , Bertrand Arnulf , Krina Patel , Michele Cavo , Ajay K. Nooka , Salomon Manier , Natalie Callander , Luciano J. Costa , Ravi Vij , Nizar J. Bahlis , Philippe Moreau , Scott R. Solomon , Ingerid Weum Abrahamsen , Rachid Baz , Annemiek Broijl , Christine Chen , Sundar Jagannath , Noopur Raje , Michel Delforge , Reuben Benjamin , Thomas Pabst , Shinsuke Iida , Jesus Berdeja , Anna Truppel-Hartmann , Rashmi Bhatnagar , Fan Wu , Julia Piasecki , Laurie Eliason , Devender Dhanda , Jasper Felten , Andrea Caia , Mark Cook , Mihaela Popa Mckiver , Sergio Giralt ONCOLOGY RESEARCH AND TREATMENT（2024）
Key words
International Myeloma Working Group
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
